Leukemia
Acute Myeloid Leukemia: Public Health and Genomics - September 17, 2015
Toward individualized therapy in acute myeloid leukemia: A contemporary review
Kadia TM et al. JAMA Oncology, September 16, 2015
Kadia TM et al. JAMA Oncology, September 16, 2015
Molecular genetic markers in acute myeloid leukemia.
Yohe S et al. J Clin Med 2015 (3) 460-78
Yohe S et al. J Clin Med 2015 (3) 460-78
The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.
Lavallée VP et al. Nat. Genet. 2015 Sep (9) 1030-1037
Lavallée VP et al. Nat. Genet. 2015 Sep (9) 1030-1037
Toward individualized therapy in acute myeloid leukemia: A contemporary review.
Kadia TM et al. JAMA Oncol 2015 Apr 30.
Kadia TM et al. JAMA Oncol 2015 Apr 30.
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia.
Gallipoli P et al. Ther Adv Hematol 2015 Jun (3) 103-19
Gallipoli P et al. Ther Adv Hematol 2015 Jun (3) 103-19
Why is progress in acute myeloid leukemia so slow?
Estey E et al. Semin. Hematol. 2015 Jul (3) 243-8
Estey E et al. Semin. Hematol. 2015 Jul (3) 243-8
Next-generation sequencing and detection of minimal residual disease in acute myeloid leukemia: ready for clinical practice?
Pastore F et al. JAMA 2015 Aug 25. 314(8) 778-780
Pastore F et al. JAMA 2015 Aug 25. 314(8) 778-780
Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia.
Klco JM et al. JAMA 2015 Aug 25. 314(8) 811-822
Klco JM et al. JAMA 2015 Aug 25. 314(8) 811-822
Acute Lymphoblastic Leukemia: Pharmacogenomic Insights - June 1, 2015
The pharmacogenomics of Vincristine-induced neuropathy: On pins and needles
Berg SL et al. JAMA Oncology, May 29, 2015
Berg SL et al. JAMA Oncology, May 29, 2015
Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.
Mei L et al. Blood Rev. 2015 Jan 10.
Mei L et al. Blood Rev. 2015 Jan 10.
Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.
Pui Ching-Hon et al. Front Med 2015 Mar (1) 1-9
Pui Ching-Hon et al. Front Med 2015 Mar (1) 1-9
Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.
Lennard L et al. Br. J. Haematol. 2015 Apr (2) 228-40
Lennard L et al. Br. J. Haematol. 2015 Apr (2) 228-40
Pharmacogenetics of childhood acute lymphoblastic leukemia.
Lopez-Lopez E et al. Pharmacogenomics 2014 Jul (10) 1383-98
Lopez-Lopez E et al. Pharmacogenomics 2014 Jul (10) 1383-98
Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?
Hoang Phuong TV et al. Br J Clin Pharmacol 2015 Mar (3) 429-40
Hoang Phuong TV et al. Br J Clin Pharmacol 2015 Mar (3) 429-40
Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
Dulucq S et al. Expert Opin Drug Metab Toxicol 2014 May (5) 699-719
Dulucq S et al. Expert Opin Drug Metab Toxicol 2014 May (5) 699-719
Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia.
López-López E et al. PLoS ONE 2014 (3) e91261
López-López E et al. PLoS ONE 2014 (3) e91261
Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?
Kodidela S et al. Eur. J. Clin. Pharmacol. 2014 Mar (3) 253-60
Kodidela S et al. Eur. J. Clin. Pharmacol. 2014 Mar (3) 253-60
Pharmacogenetics of childhood acute lymphoblastic leukemia, by E Lopez-Lopez et al, Medscape, 2014
No hay comentarios:
Publicar un comentario